Nanowired Drugs Could Treat Patients with Parkinson’s or Alzheimer’s
U of A doctoral student used titanate nanowires treated with the drug cerebrolysin to target delivery to the brain and central nervous system.
Millions of Americans suffer from neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Researchers have identified promising new treatments, such as cerebrolysin, but current clinical approaches are ineffective because critical concentrations of the drug dissipate within the body before reaching the blood-brain barrier and central nervous system.
To address this problem, researchers have focused on various delivery vehicles for sustained and targeted drug release. An effective, targeted approach would eliminate the need for inefficient, high dosages that cause adverse side effects.
In recent years, biomedical engineers have experimented with nanomaterials as an approach to targeted delivery. Under the direction of Ryan Tian, associate professor of chemistry at the University of Arkansas, doctoral student Asya Ozkizilcik has improved the nanowiring of drugs for an international team of researchers who are working on a new method for treating neurodegenerative diseases.
Click here to read more.
Winter Clinics for Cranial and Spinal Surgery
Feb. 25, 2018 - Mar. 1, 2018; Snowmass Village, Colo.
69th Southern Neurosurgical Society Annual Meeting
Feb. 28, 2018 - Mar. 3, 2018; San Juan, PR
Second International Brain Mapping Course
April 26-27, 2018; New Orleans
2018 AANS Annual Scientific Meeting
April 28-May 2, 2018; New Orleans
2018 American Society for Stereotactic and Functional Neurosurgery Biennial Meeting
Jun. 2, 2018 - Jun. 5, 2018; Denver
Be the first to reply using the above form.